Division of Infectious Diseases, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
UNC Healthcare, Chapel Hill, NC, USA.
Transpl Infect Dis. 2021 Feb;23(1):e13452. doi: 10.1111/tid.13452. Epub 2020 Sep 12.
Sulfonamides are recommended as part of first-line therapy for most Nocardia infections, with trimethoprim-sulfamethoxazole (TMP-SMX) considered the drug of choice for susceptible isolates. However, in the case of central nervous system, disseminated disease, and other serious Nocardia infections, TMP-SMX should not be used as monotherapy. The preferred treatment for a patient unable to take TMP-SMX because of allergy or intolerance remains uncertain. Prior to the availability of TMP-SMX in 1973, other sulfonamides were mainstays of treatment. We describe a Nocardia infection successfully treated with sulfadiazine in a lung transplant recipient who could not tolerate TMP-SMX. A review of similar cases reported in the literature provides insight into the successful treatment of Nocardia infections with sulfonamide regimens not containing trimethoprim in transplant recipients and other immunocompromised hosts.
磺胺类药物被推荐作为大多数诺卡氏菌感染的一线治疗药物,其中复方磺胺甲噁唑(TMP-SMX)被认为是敏感分离株的首选药物。然而,对于中枢神经系统、播散性疾病和其他严重的诺卡氏菌感染,TMP-SMX 不应该作为单一药物使用。由于过敏或不耐受而不能使用 TMP-SMX 的患者的首选治疗方法仍不确定。在 1973 年 TMP-SMX 上市之前,其他磺胺类药物是治疗的主要药物。我们描述了一名肺移植受者成功地用磺胺嘧啶治疗了不能耐受 TMP-SMX 的诺卡氏菌感染。对文献中报告的类似病例的回顾提供了一些见解,了解了在移植受者和其他免疫功能低下宿主中,使用不含甲氧苄啶的磺胺类药物方案成功治疗诺卡氏菌感染的情况。